Presentation by E. Leahy Prevention/ reduction of pathology in AD models hasn’t translated to improved cognitive performance in patients. This advocates more refined assessment of behavioral effects of drugs in Alzheimer’s models. The talk will describe how high...
T. HANANIA1, L. HARDY2, S. HOPKINS2, N. POOLA2, K. KOBLAN2, E. LEAHY1 1PsychoGenics, Inc., Paramus, NJ, USA; 2Sunovion Pharmaceuticals, 84 Waterford Drive, Marlborough, MA, USA Most of the neuropsychiatric disorders are polygenic and involve multiple neuronal...
Want to get in touch? Connect with the PsychoGenics research team.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.